Relation of Leptin and Tumor Necrosis Factor α to Body Weight Changes in Patients with Pulmonary TuberculosisÇakır B.a · Yönem A.b · Güler S.a · Odabaşı E.b · Demirbaş B.a · Gürsoy G.a · Aral Y.a
aDepartment of Endocrinology and Metabolism, Ankara Education and Research Hospital, and bDepartment of Endocrinology and Metabolism, Gülhane School of Medicine, Ankara, Turkey
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
In this study we investigated whether leptin and TNFα levels change with improvement in body weight with antituberculotic therapy in active tuberculosis patients. 30 patients (8 females and 22 males) with active pulmonary tuberculosis formed the patient group, and 25 sex- and age-matched healthy subjects (8 females and 17 males) served as the control group. Body weight, body mass index (BMI) and serum leptin and plasma TNFα levels are measured before and in the sixth month of therapy in all patients. Before the initiation of therapy, BMI of the patients was significantly lower than BMI of the controls (20.2 ± 1.6 vs. 25.2 ± 2.7 kg/m2, respectively; p < 0.05). After treatment, BMI of the patients increased significantly to 21.4 ± 1.9 kg/m2 (p < 0.05), but was still lower than that of the controls (p < 0.05). Pretreatment serum leptin (4.5 ± 0.9 vs. 2.1 ± 0.2 ng/ml, respectively; p < 0.05) and plasma TNFα (27.9 ± 3.4 vs. 23.9 ± 3.0 pg/ml, respectively; p < 0.05) levels of the patients were significantly higher than those of the controls. After treatment, serum leptin levels increased to 6.7 ± 2.2 ng/ml, but this rise was not statistically significant (p > 0.05). Treatment did not result in any significant change in TNFα levels, either. Δ leptin was highly related to Δ BMI in patients with tuberculosis (r = 0.68, p = 0.02). In the pretreatment period, there was a significant correlation between leptin and TNFα levels in the whole patient group (r = 0.78, p < 0.001), and in female (r = 0.74, p < 0.001) and male patients separately (r = 0.74, p = 0.035). In conclusion, leptin and TNFα may be responsible for the weight loss in pulmonary tuberculosis patients, but their levels do not change with improvement in body weight with antituberculotic treatment.
© 2000 S. Karger AG, Basel
- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of mouse obese gene and its human homologue. Nature 1994;372:425–432.
- Sinha MK: Human leptin: The hormone of adipose tissue. Eur J Endocrinol 1997;136:461–464.
- Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stevens TW, Nyce MR, Ohannesian JP, Marco CC, McKee U, Bauer TL, Caro IF: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292–295.
Davies PDO (ed): Clinical Tuberculosis. Chapman & Hall Medical, London, 1994, pp 63–70.
- Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 1987;316:379–385.
- Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409–2415.
- Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway F, Pan A, Garvey WT: The metabolic significance of leptin in humans: Gender-based differences in relationship to adiposity, insulin sensitivity and energy expenditure. J Clin Endocrinol Metab 1997;82:1293–1300.
- Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P: Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546–549.
- Socher SH, Friedman A, Martinez D: Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice. J Exp Med 1988;167:1957–1962.
Michie HR, Sherman ML, Spriggs OR, Rounds J, Christie M, Wilmore DW: Chronic TNF infusion causes anorexia but not accelerated nitrogen loss. Ann Surg 1989;209:19–24.
- Sarraf P, Frederich RC, Turner EM, Ma G, Jaskowiak NT, Rivet DJ III, Flier JS, Lowell BB, Fraker DL, Alexander HR: Multiple cytokines and acute inflammation raise mouse leptin levels: Potential role in inflammatory anorexia. J Exp Med 1997;185:171–175.
- Moshyedi AK, Josephs MD, Abdalla EK, Mackay SL, Edwards CK III, Copeland EM III, Moldawer LL: Increased leptin expression in mice with bacterial peritonitis is partially regulated by tumor necrosis factor alpha. Infect Immun 1998;66:1800–1802.
- Zumbach MS, Boehme MW, Wahl P, Stremmel W, Ziegler R, Nawroth PP: Tumor necrosis factor increases serum leptin levels in humans. J Clin Endocrinol Metab 1997;82:4080–4082.
- Corica F, Allegra A, Corsonello A, Buemi M, Calapai G, Ruello A, Nicita Mauro V, Ceruso D: Relationship between plasma leptin levels and the tumor necrosis factor-α system in obese subjects. Int J Obes Relat Metab Disord 1999;23:355–360.
- Bemelmans MHA, van Tits LJH, Buurman WA: Tumor necrosis factor: Function, release and clearance. Crit Rev Immunol 1996;16:1–11.
- Samsonov MY, Tilz GP, Egorova O, Reibnegger G, Balabanova RM, Nassonov EL, Nassonova VA, Wachter H, Fuchs D: Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995;4:29–32.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.